About: Use of MMP‐8 and MMP‐9 to assess disease severity in children with viral lower respiratory tract infections

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Use of MMP‐8 and MMP‐9 to assess disease severity in children with viral lower respiratory tract infections Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Use of MMP‐8 and MMP‐9 to assess disease severity in children with viral lower respiratory tract infections
Creator	Ferwerda, Gerben Ahout, Inge Warris, Adilia Brand, Kim De Groot, Ronald Hermans, Peter
source	Medline; PMC
abstract	Matrix metalloproteinases (MMPs) play an important role in respiratory inflammatory diseases, such as asthma and chronic obstructive pulmonary disease. It was hypothesized that MMP‐8 and MMP‐9 may function as biological markers to assess disease severity in viral lower respiratory tract infections in children. MMP‐8 and MMP‐9 mRNA expression levels in peripheral blood mononuclear cells (PBMCs) and granulocytes obtained in both the acute and recovery phase from 153 children with mild, moderate, and severe viral lower respiratory tract infections were determined using real‐time PCR. In addition, MMP‐8 and MMP‐9 concentrations in blood and nasopharyngeal specimens were determined during acute mild, moderate, and severe infection, and after recovery using ELISA. Furthermore, PBMCs and neutrophils obtained from healthy volunteers were stimulated with RSV, LPS (TLR4 agonist), and Pam3Cys (TLR2 agonist) in vitro. Disease severity of viral lower respiratory tract infections in children is associated with increased expression levels of the MMP‐8 and MMP‐9 genes in both PBMCs and granulocytes. On the contrary, in vitro experiments showed that MMP‐8 and MMP‐9 mRNA and protein expression in PBMCs and granulocytes is not induced by stimulation with RSV, the most frequent detected virus in young children with viral lower respiratory tract infections. These data indicate that expression levels of the MMP‐8 and MMP‐9 genes in both PBMCs and neutrophils are associated with viral lower respiratory tract infections disease severity. These observations justify future validation in independent prospective study cohorts of the usefulness of MMP‐8 and MMP‐9 as potential markers for disease severity in viral respiratory infections. J. Med. Virol. 84:1471–1480, 2012. © 2012 Wiley Periodicals, Inc.
has issue date	2012-07-18(xsd:dateTime)
bibo:doi	10.1002/jmv.23301
bibo:pmid	22825827
has license	no-cc
sha1sum (hex)	22e1957bcb7b0dbc5cfb2d41e16afe57c6279483
schema:url	https://doi.org/10.1002/jmv.23301
resource representing a document's title	Use of MMP‐8 and MMP‐9 to assess disease severity in children with viral lower respiratory tract infections
has PubMed Central identifier	PMC7167016
has PubMed identifier	22825827
schema:publication	J Med Virol
resource representing a document's body	covid:22e1957bcb7b0dbc5cfb2d41e16afe57c6279483#body_text
is schema:about of	named entity 'mild' named entity 'nasopharyngeal' named entity 'stimulated' named entity 'MMP-9' named entity 'PBMCs' named entity 'prospective study' named entity 'MMP-9' named entity 'levels' named entity 'concentrations' named entity 'respiratory infections' named entity 'expression' named entity 'MMP-9' named entity 'RECOVERY' named entity 'CHRONIC OBSTRUCTIVE PULMONARY DISEASE' named entity 'VALIDATION' named entity 'ASSESS' named entity 'ROLE' named entity 'CHILDREN' named entity 'asthma' named entity 'expression' named entity 'specimens' named entity 'PBMCs' named entity 'MMP-9' named entity 'disease' named entity 'blood' named entity 'frequent' named entity 'viral' named entity 'LPS' named entity 'future' named entity 'genes' named entity 'PBMCs' named entity 'biological markers' named entity 'levels' named entity 'determined' named entity 'MMP-8' named entity 'neutrophils' named entity 'young children' named entity 'expression levels' named entity 'PCR' named entity 'PBMCs' named entity 'respiratory infections' named entity 'lower respiratory tract infections' named entity 'mRNA expression' named entity 'lower respiratory tract infections' named entity 'MMP-8' named entity 'RSV' named entity 'MMP-8' named entity 'lower respiratory tract infections' named entity 'MMP-8' named entity 'virus' named entity 'MMP-9' named entity 'MMP-9' named entity 'MMPs' named entity 'PBMCs' named entity 'MMP-8' named entity 'MMP-9' named entity 'nasopharyngeal' named entity 'Granulocytes' named entity 'TIMP-1' named entity 'MMP-8' named entity 'plasma' named entity 'MMP-8' named entity 'MMP-8' named entity 'human metapneumovirus' named entity 'plasma' named entity 'MMP-9' named entity 'PCR reaction' named entity 'MMP-8' named entity 'gene expression' named entity 'leukocytes' named entity 'MMP-9' named entity 'milliliters' named entity 'MMP-8' named entity 'MMP-8' named entity 'acute lung injury' named entity 'MMP-9'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software